Evolution of Small Molecule Kinase Drugs
- 18 December 2018
- journal article
- research article
- Published by American Chemical Society (ACS) in ACS Medicinal Chemistry Letters
- Vol. 10 (2), 153-160
- https://doi.org/10.1021/acsmedchemlett.8b00445
Abstract
The development of small molecule kinase drugs is a rapidly evolving field and represents one of the most important research areas within oncology. This innovation letter provides an overview and analysis of approved kinase drugs according to their WHO registration (INN) dates, primary biological targets, and selectivity and structural similarities, which are also depicted in an associated poster. It also discusses new trends in kinase drug discovery programs such as new kinase targets, novel mechanisms of action, and diverse indications.Keywords
This publication has 50 references indexed in Scilit:
- Rapamycin passes the torch: a new generation of mTOR inhibitorsNature Reviews Drug Discovery, 2011
- Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivityNature Biotechnology, 2011
- Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal–Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK)Journal of Medicinal Chemistry, 2011
- Discovery of a Highly Potent and Selective MEK Inhibitor: GSK1120212 (JTP-74057 DMSO Solvate)ACS Medicinal Chemistry Letters, 2011
- The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATPProceedings of the National Academy of Sciences of the United States of America, 2008
- A quantitative analysis of kinase inhibitor selectivityNature Biotechnology, 2008
- Tamoxifen (ICI46,474) as a targeted therapy to treat and prevent breast cancerBritish Journal of Pharmacology, 2006
- A small molecule–kinase interaction map for clinical kinase inhibitorsNature Biotechnology, 2005
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to GefitinibThe New England Journal of Medicine, 2004
- Glivec (STI571, imatinib), a rationally developed, targeted anticancer drugNature Reviews Drug Discovery, 2002